Cardiovascular outcome trials in diabetes: what have we learnt?
|
|
- Curtis Carson
- 5 years ago
- Views:
Transcription
1 Diabetes Cardiovascular outcome trials in diabetes: what have we learnt? Mike Kirby, GP and Visiting Professor, The University of Hertfordshire and The Prostate Centre, London; Nick Boon, Honorary Reader, University of Edinburgh Diabetes and its cardiovascular complications are a major cause of morbidity and mortality in men. Over recent years a plethora of new drugs with novel modes of action have been introduced and tested in clinical trials. In this article the authors look at the results of these trials and discuss how the drugs might help in the battle against diabetes in men. In 2015, 6.7% of men had doctordiagnosed diabetes compared to 5.1% of women. 1 The recent report One in ten: the male diabetes crisis, published by the Men s Health Forum charity last year, demonstrated that one in ten men in the UK now have either type 1 or type 2 diabetes mellitus (T2DM), and the incidence is predicted to triple over the next 30 years. 2 Men are more likely to be overweight and to develop T2DM than women, and they do so at younger ages and lower average weights. Men are also more likely to suffer diabetic complications. The data showed that 59.6% of those who see a healthcare professional with a foot ulcer are men and that they are twice as likely as women to require amputation. More men die, and die prematurely, as a result of diabetes. 2 Cardiovascular (CV) disease is the major threat to people with diabetes. Lente insulins Metformin Sulphonyureas Monocomponent insulins Diabetes new drug development significantly increased in the late 1990s when a series of novel classes of drugs started to become available (DPP4 = dipeptidyl peptidase-4; GLP-1 = glucagon like peptide-1; SGLT2 = sodium glucose transporter 2) It accounts for more than 50% of deaths in this population and leads to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2DM and CV disease, compared with the general population. 3 Until now, attempts to lower CV risk by means of glucose-lowering treatment alone have proved disappointing. Early trials suggested that this was possible, but subsequent research was unable to verify the original observations and concerns arose that some glucoselowering drugs could actually cause cardiovascular harm. This led to demands for mandatory CV outcome trials, a large number of which have now been performed or are ongoing. Some of the key findings of these trials include some surprising and highly rewarding benefits of the Recombinant insulins Alpha glucosidase inhibitors, meglitinides, thiazolidinediones 2 nd generation sulphonylureas Insulin aspart and lispro DPP-4 inhibitor rd generation sulphonylureas GLP-1 agonist SGLT2 inhibitor 2012 sodium glucose transporter 2 (SGLT2) inhibitors and the glucagonlike peptide-1 (GLP-1) agonists. 4 However, we must not forget that metformin, a guanidine derivative that was found in the French lilac Galega officinalis more than 50 years ago, remains the most widely used drug for the treatment of T2DM, and continues to be recommended by major clinical guidelines as first-line therapy and in combination with any other blood glucose-lowering drugs. 5 Metformin s hypoglycaemic effect stems from an insulin-sensitising action on both the liver, resulting in decreased glucose release, and to a lesser extent on the peripheral tissues, where it increases glucose uptake. 6 A recent paper looks at the effect of metformin on epigenomics, microrna levels and subsequent Insulin degludec trendsinmenshealth.com Trends in Urology & Men s Health July/August
2 Diabetes gene expression in diabetes and its potential clinical implications. 7 A recent review of metformin s effects on the heart and the CV system concluded that the overall evidence accumulated from both clinical trials and real-world registry favours a protective effect of metformin relating to both coronary events and progression to heart failure. In light of this potential, its efficacy, safety and low cost, metformin should remain the mainstay of T2DM therapy. 5 Second-line antidiabetic therapy The effect of novel second-line antidiabetic therapy on CV risk has been examined in many trials, but it is important to appreciate that: Most of these trials were designed to demonstrate non-inferiority and did not therefore have the statistical power to reliably detect potentially significant benefit. All these trials used a composite primary endpoint (eg CV death, non-fatal myocardial infarction and non-fatal stroke). While this approach improves the statistical power of the study, it has many drawbacks. For example, it is possible that intervention may increase one element of a composite endpoint and reduce another, producing a null effect overall. Equally, it is selfevident that some elements of a composite endpoint, most notably death, should carry more weight than others (eg hospitalisation for heart failure). Almost all of these trials were placebo-controlled and do not therefore directly address the question of which drug to select from the many options once metformin monotherapy and optimum CV risk factor reduction (blood pressure control, statin therapy, etc) have been initiated. Indeed, only direct comparisons of equipotent drug regimens can do this. The inclusion criteria differed greatly. Most trials only included patients with T2DM who either had or were deemed to be at high risk of developing CV disease. The results cannot therefore be easily extrapolated to lower-risk subjects. The drugs being evaluated have numerous pleiotropic effects, so it should not be assumed that any changes in CV outcome are mediated by lowering blood sugar. On the other hand, a specific cardiovascular effect can only be inferred if both arms of a study produce equally good diabetic control. It may also be difficult to determine if the observed effects apply to all drugs in the same class. Obviously, CV outcomes are not the only consideration in choosing a diabetes drug and differences in blood glucose-lowering, side-effect profiles, and cost and convenience must all be factored into decisionmaking. Nevertheless, in spite of these reservations, it seems clear that there are important differences in the likely impact of common diabetes therapies on cardiovascular risk that should influence therapeutic choices. Sulfonylureas The sulfonylureas (eg glipizide, glimepiride) are the most commonly prescribed class of oral agents after metformin and offer a well-tolerated means of lowering blood glucose concentrations. Some randomised controlled trials 8 10 and observational studies 11 have reported that sulfonylurea treatment is associated with higher rates of CV events when compared to metformin. However, it is not clear if this reflects the hazards of sulfonylurea therapy or the specific benefits of metformin. The sulfonylureas lower blood glucose by stimulating pancreatic beta cell insulin secretion. It is conceivable that they may promote CV events by inducing recurrent hypoglycaemia with secondary increases in heart rate, vascular inflammation, platelet aggregation and pro-arrhythmia. 12 Thiazolidinediones Although these antidiabetic drugs were introduced in the late 1990s, fears that they may increase CV risk did not emerge until 2007 when a meta-analysis of 42 trials of rosiglitazone therapy reported higher rates of myocardial infarction (MI) (odds ratio [OR] 1.43; 95% confidence interval [CI] ; p=0.03) and CV death (OR 1.64; 95% CI, ; p=0.06). 13 This triggered intense debate and prompted the FDA to introduce stringent proof of CV safety for new antidiabetic agents; it also led to a huge reduction in the use of rosiglitazone and numerous followup studies. There is now no doubt that the PPAR-gamma agonists rosiglitazone and pioglitazone both substantially increase the risk of heart failure by promoting potentially reversible fluid retention. However, it is not clear if this has important adverse long-term consequences. Moreover, the impact of these drugs on other CV endpoints is not so clear. 14 In the RECORD trial, rosiglitazone increased the risk of heart failure but did not significantly increase the risk of death, MI or stroke. 15 Unfortunately, the validity of these findings has been questioned because the overall event rate in this study was much lower than expected. In contrast to rosiglitazone, pioglitazone, has never been reported to increase the risk of MI or other macrovascular adverse events. Indeed, a large CV outcome trial (PROactive) reported a borderline significant reduction in the composite of MI and stroke (hazard ratio [HR] 0.90, 95% CI ), albeit with a substantial increase in 8 Trends in Urology & Men s Health July/August 2018 trendsinmenshealth.com
3 Diabetes severe heart failure events (HR 1.41; 95% CI ; p<0.007). 16 Moreover, pioglitazone has numerous potentially beneficial effects on important CV risk factors (eg insulin sensitivity, blood pressure, triglycerides, HDL cholesterol, and markers of inflammation) in addition to lowering plasma glucose and, interestingly, was reported to reduce the composite risk of stroke and MI in a study of non-diabetic patients with a history of recent stroke or transient ischaemic attack. 17 SGLT 2 inhibitors These drugs (empagliflozin, canagliflozin, and dapagliflozin) lower blood glucose by increasing urinary glucose excretion and have been reported to improve many CV risk factors, including blood pressure, body weight, visceral adiposity, hyperinsulinemia, albuminuria, serum uric acid and oxidative stress. Not surprisingly, the use of these drugs is also associated with higher rates of urinary and genital infection. In the EMPA-REG trial, empagliflozin was reported to reduce CV death by 38% (3.7% versus 5.9%) (Figure 1) and allcause death by 32% (5.7% versus 8.3%). 18 Heart failure hospitalisations were significantly decreased by 35% (2.7% versus 4.1%). Treatment with empagliflozin was also associated with a marked reduction in incident or worsening nephropathy and modest reductions in weight and blood pressure, but there was no apparent effect on rates of lower limb amputation, MI or stroke. Canagliflozin was found to have similar effects in the CANVAS trial, including a 14% reduction in the primary endpoint of CV death, non-fatal MI or non-fatal stroke, a 22% reduction in death from CV causes or hospitalisation for heart failure, and a 40% reduction in worsening nephropathy. 19 In Cardiovascular death (%) Empagiflozin Placebo Month Figure 1. Deaths from cardiovascular causes were significantly reduced by empagiflozin in the EMPA-REG trial (hazard ratio 0.62; 95% CI ; p<0.001) 18 contrast to the EMPA-REG trial, amputation risk was increased in the canagliflozin cohort (6.3 versus 3.4 participants per 1000 patientyears; HR 1.97; 95% CI, ). The mechanism of these CV benefits is not yet understood, but it seems likely that they are at least partly attributable to simple osmotic diuresis and natriuresis. However, very interestingly, these drugs seem to have a striking effect on the risk of cardiac death that is apparent within weeks of starting therapy (Figure 1), with relatively little impact on the risk of MI, stroke and other atheroma related adverse events. It seems possible that this is mediated by beneficial effects on myocardial metabolism, haemodynamic effects and an increase in ketone bodies, which may provide the failing myocardium with a more efficient fuel source SGLT2 inhibitors may also mitigate the fluid retention associated with pioglitazone. 23 It is possible that the reduction in CV death with empagliflozin is partly related to the change in sodium and glucose handling in the kidneys, leading to reductions in fluid burden, ventricular stress and, consequently, the risk of sudden cardiac failure. GLP-1 agonists The GLP-1 agonists lower blood glucose and promote weight loss by increasing insulin secretion, reducing glucagon levels and delaying gastric emptying. A range of injectable agents are available (albiglutide, exenatide, dulaglutide, liraglutide, lixisenatide and semaglutide) and there is growing evidence that these drugs can improve CV outcomes. The Liraglutide Effect and Action in Diabetes (LEADER) study in patients with T2DM and additional CV risk factors reported that liraglutide improved the primary outcome, a composite of CV, non-fatal MI and non-fatal stroke (HR 0.87; 95% CI ), and significantly reduced all-cause death (HR 0.85, 95% CI ) (Figure 2). 24 A post-hoc analysis showed that numerically fewer MIs were associated with CV death with liraglutide versus placebo (17 versus 28 fatal MI, p=0.28). 25 A non-inferiority study of onceweekly semaglutide (SUSTAIN 6) also reported a positive effect on the same trendsinmenshealth.com Trends in Urology & Men s Health July/August
4 Diabetes primary outcome of cardiovascular death, non-fatal MI and non-fatal stroke (HR 0.74; 95% CI ). 26 However, this result was largely driven by lower rates of non-fatal stroke and non-fatal MI with little or no effect on mortality. Both of these studies reported a reduction in nephropathy events and little or no effect on heart failure events. Semaglutide but not liraglutide treatment was associated with an increase in incident retinopathy that merits further investigation. In contrast to these studies, a third large clinical trial of the GLP-1 agonist lixisenatide was negative. 27 The mechanism of the potentially important CV benefits of GLP-1 agonists is not clear but is probably multifactorial. Moreover, it appears to be quite distinct from the action of the SGLT2 inhibitors: the event curves certainly take longer to diverge and most of the benefits appear to be associated with atheroma-related events as opposed to some form of myocardial protection. Weight loss is likely to be an important factor and there is growing interest in the potential to use these drugs to treat obesity. Dipeptidyl peptidase-4 (DPP-4) inhibitors The DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin and sitagliptin) prevent the breakdown of endogenous incretins and, like the GLP-1 agonists, increase insulin and decrease glucagon levels. They can, however, be given orally and do not inhibit gastric emptying. Three large CV outcome trials among patients with T2DM and high CV risk have reported neutral effects on their primary composite endpoints (HR of 0.96, 1.00 and 0.98 for alogliptin, saxagliptin, and sitagliptin, respectively) (Table 1) There is, however, some evidence, most notably from the SAVOR-TIMI 53 trial, 29 that these agents may increase the risk of hospitalisation for heart failure. All cause death (%) Liraglutide Placebo Time from randomisation (months) Figure 2. The effect of liraglutide on all-cause death in the LEADER trial (hazard ratio 0.85; 95% CI ; p=0.002) 24 On the other hand, observational studies and meta-analyses have consistently suggested that DPP-4 inhibitors may produce better CV outcomes than sulfonylureas. 11,31 The results of CAROLINA (a CV outcome trial comparing linagliptin with glimiperide), due later this year, are therefore eagerly awaited. Conclusions In the past, the treatment of diabetes has focused on glycaemic control and the prevention of microvascular disease using treatment strategies designed to lower glycated haemoglobin levels, minimise hyperglycaemia-related symptoms, such as polyuria, and reduce the risk of developing microvascular complications, namely retinopathy, nephropathy and neuropathy. 32 In contrast, the prevention of macrovascular events has been addressed by targeting other CV risk factors, particularly hyperlipidaemia and hypertension, with a major emphasis on the use of ACE inhibitors, angiotensin-receptor blocking drugs and statins. 33 The results of the CV outcome trials discussed in this article offer exciting new possibilities. At present, a combination of metformin, pioglitazone, an SGLT2 inhibitor and liraglutide appears to be the optimal cocktail of medications for improving both glycaemic control and CV outcomes for people with T2DM at high CV risk. Such a combination may not only prevent CV events, but may also save lives. 34 Nevertheless, treatment strategies must take account of many factors, including renal function, weight and side-effects, and will undoubtedly evolve as the results of new trials become available. Declaration of interests: Mike Kirby has received funding from the pharmaceutical industry for research, conference attendance, lecturing and advice. Nick Boon has received research grants, lecture fees and advisory board fees from the pharmaceutical industry and was a member of the SUSTAIN 6 trial data monitoring committee. References 1. NHS. Health Survey for England, 2015: trend tables adult tables ( nhs.uk/catalogue/pub22616; accessed 24 May 2018). 10 Trends in Urology & Men s Health July/August 2018 trendsinmenshealth.com
5 Diabetes Study (year published) Randomisation Number of patients Key findings Thiazolidinediones PROACTIVE (2005) 15 Pioglitazone vs placebo 5238 No significant difference in the primary endpoint composite of all-cause mortality, non-fatal myocardial infarction (MI), stroke, acute coronary syndrome, endovascular or surgical intervention in the coronary or leg arteries (HR 0.90; 95% CI , p=0.095). Significant reduction in the secondary endpoint composite of all-cause mortality, non-fatal MI and stroke (HR 0.84; 95% CI ; p=0.027). Significant increase in serious heart failure events (5.7% vs 4.1%; p=0.007) but no excess mortality among these heart failure patients. RECORD Rosiglitazone + (2009) 14 metformin/sulfonylurea vs metformin + sulfonylurea 4447 No difference in the primary endpoint of CV hospitalisation or CV death (non-inferiority margin 1.20). Higher rates of heart failure and fracture, lower rates of MI and stroke. SGLT2 inhibitors EMPA-REG (2015) 17 Empagliflozin vs placebo 7020 CV death reduced by 38% (3.7% vs 5.9%) and all-cause death by 32% (5.7% vs 8.3%). Heart failure hospitalisations decreased by 35% and new onset or worsening nephropathy was reduced by 35%. CANVAS (2017) 18 Canagliflozin vs placebo Composite of CV death, non-fatal MI and non-fatal stroke (MACE) reduced by 14% (p<0.001 for non-inferiority; p=0.02 for superiority). 27% reduction in progression of albuminuria and 97% increase in amputations. GLP-1 agonists LEADER Liraglutide vs placebo 9540 Significant reductions in all-cause death (HR 0.85, 95% CI (2016) ) and MACE (HR 0.87; 95% CI ). SUSTAIN 6 Semaglutide vs placebo 3297 Significant reduction in MACE (HR 0.74; 95% CI ) (2016) 24 but not all-cause or CV death alone. ELIXA (2015) 25 Lixisenatide vs placebo 6068 No significant difference in CV outcomes DPP-4 inhibitors EXAMINE Alogliptin vs placebo 5380 No difference in major CV endpoints (MACE) (2013) 26 SAVOR TIMI 53 Saxagliptin vs placebo No difference in MACE. Increased hospitalisation for heart (2013) 27 failure (3.5% vs 2.8%) TECOS (2015) 28 Sitagliptin vs placebo No difference in MACE Table 1. Major randomised placebo-controlled clinical trials reporting the effects of novel antidiabetic therapy on cardiovascular outcomes (CV) in type 2 diabetes mellitus trendsinmenshealth.com Trends in Urology & Men s Health July/August
6 Diabetes 2. Baker P. One in ten: the male diabetes crisis. Men s Health Forum, 2017 (https: // -ten-male-diabetes-crisis; accessed 24 May 2018). 3. Schernthaner G, Khunti K, Lotan C, et al. Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). Ther Clin Risk Manag 2017;13: Rydén L, Shahim B, Mellbin L. Clinical implications of cardiovascular outcome trials in type 2 diabetes: from DCCT to EMPA-REG. Clin Ther 2016;38: Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data. Nutr Metab Cardiovasc Dis 2017;27: Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2016;49: Bridgeman SC, Ellison GC, Melton PE, et al. Epigenetic effects of metformin: from molecular mechanisms to clinical implications. Diabetes Obes Metab doi: /dom [Epub ahead of print]. 8. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;36: Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15: Phung O, Schwartzman E, Allen R, et al. Sulfonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013;30: Morgan C, Mukherjee J, Jenkins- Jones S, et al. Combination therapy with metformin plus sulfonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014;16: Desouza C, Bolli G, Fonesca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33: Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356: Flory JH, Ukena JK, Floyd JS. Novel anti-glycemic drugs and reduction of cardiovascular risk in diabetes: expectations realized, promises unmet. Curr Atheroscler Rep 2016;18: Home P, Pocock S, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373: Dormandy JA, Charbonnel B, Eckland EJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone: the PROactive Study. Lancet 2005;366: Kernan W, Viscoli C, Furie K, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374: Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377: Ryder REJ, De Fronzo RA. Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: the optimal combination may be metformin, pioglitazone and empagliflozin. Br J Diabetes Vasc Dis 2015;15: Ryder REJ, DeFronzo RA. Diabetes medications with cardiovascular protection - what now after LEADER? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives? Br J Diabetes 2016;16: Abdul-Ghani M, DeFronzo RA, Del Prato S, et al. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? Diabetes Care 2017;40: Gautam A, Agrawal PK, Prakash P, et al. Pioglitazone associated with pedal edema resolved by adding sodium glucose co-transporter 2 inhibitor. ADA 76th Scientific Sessions 2016, poster 140-LB ( com/pp8/#!/4008/presentation/44543; accessed 24 May 2018). 24. Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375: Marso SP, Nauck MA, Fries TM, et al. Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the LEADER trial). Am J Cardio doi: /j.amjcard [Epub ahead of print]. 26. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375: Pfeffer M, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: White W, Cannon C, Heller S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369: Scirica B, Bhatt D, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369: Green J, Bethel M, Armstrong P, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373: Ou S, Shih C, Chao P, et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 2015;163: Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ 2017;356:i Purga SL, Sidhu M, Farkouh M, et al. Recent insights into pharmacologic cardiovascular risk reduction in type 2 diabetes mellitus. Cardiovasc Drugs Ther 2017;31: Ryder REJ, Defronzo RA. What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives? Br J Diabetes 2017;17: Trends in Urology & Men s Health July/August 2018 trendsinmenshealth.com
Current principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationGUIDANCE UPDATE TYPE 2 DIABETES AN OVERVIEW OF THE SIGN GUIDELINE ON PHARMACOLOGICAL MANAGEMENT OF GLYCAEMIC CONTROL.
TYPE 2 DIABETES AN OVERVIEW OF THE SIGN GUIDELINE ON PHARMACOLOGICAL MANAGEMENT OF GLYCAEMIC CONTROL GUIDANCE UPDATE cpd credits Production of this Guidelines supplement has been funded by an educational
More informationCardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add?
Editorial Page 1 of 5 Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add? Keith C. Ferdinand, Indrajeet Mahata Department of Medicine, Tulane School of Medicine,
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE
CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE *Peter M. Nilsson Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden *Correspondence
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationThis house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes A debate between Dr Robert EJ Ryder 1 (for the motion) and Professor Rury
More informationSGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Diabetologia (2016) 59:1333 1339 DOI 10.1007/s00125-016-3956-x REVIEW SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Naveed Sattar 1
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationSGLT2 and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? David Preiss, 3 John J McMurray 1
SGLT2 and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Naveed Sattar, 1 James McLaren, 1 Søren L Kristensen, 2 David Preiss, 3 John J McMurray 1 1 Institute
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationDISCLOSURES. Learning objectives NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Investigator Initiated Trial Support:
NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Jane E-B Reusch MD Professor of Medicine, Biochemistry and Bioengineering Associate Director Center for Women s Health Research University of Colorado
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDiabetes Drugs and Cardiac Disease. Disclosures
Diabetes Drugs and Cardiac Disease Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco robert.rushakoff@ucsf.edu Disclosures None 1 Written Comments As I have said every
More informationManagement of CV risk in T2DM: The beginning of a new era
Diabetes Management Management of CV risk in T2DM: The beginning of a new era Muhammad Abdul-Ghani *1,2, Ralph A DeFronzo 1, Nidal Asaad 3, Amin Jayyousi 3 & Jassim Al-Suwaidi 3 Introduction Individuals
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationThe effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data
Hormones (2018) 17:83 95 https://doi.org/10.1007/s42000-018-0017-5 REVIEW The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data Panagiotis Anagnostis
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationMANAGING THE HYPERGLYCEMIA OF DIABETES: SHOULD CVOTs IMPACT MEDICATIONS?
MANAGING THE HYPERGLYCEMIA OF DIABETES: SHOULD CVOTs IMPACT MEDICATIONS? Ralph A. DeFronzo, M.D. Professor of Medicine Chief, Diabetes Division University of Texas Health Science Center San Antonio, Texas
More informationUpdates in Diabetes Care
Updates in Diabetes Care Disclosures Nothing to disclose Pharmacist Objectives 1. List strategies for improving diabetes care 2. Understand benefits and risks associated with newer pharmacotherapeutic
More informationSodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Editorial Page 1 of 5 Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes Hidekatsu Yanai Department of Internal Medicine, National Center for Global Health and Medicine
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationCOPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?
Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely? Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationPeter Stein, MD Janssen Research and Development
New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationDisclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2
Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationSIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes. A national clinical guideline November 2017.
SIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes A national clinical guideline November 2017 Evidence KEY TO EVIDENCE STATEMENTS AND RECOMMENDATIONS LEVELS OF EVIDENCE
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More information